C. Cirrincione

发表

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

D. Berry, E. Winer, E. Perez, 2006, JAMA.

Impact of symptomatic interval on prognosis of patients with stage III testicular cancer.

N. Geller, H. Scher, W. Whitmore, 1983, Urology.

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

Larry Norton, Donald A Berry, Edith A Perez, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Barbara L. Smith, Robert Livingston, Richard L Schilsky, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Arm edema in conservatively managed breast cancer: obesity is a major predictive factor.

C. Cirrincione, B. McCormick, J. Yahalom, 1991, Radiology.

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

D A Berry, D. Berry, L. Norton, 1998, Journal of the National Cancer Institute.

Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.

H. Cohen, M. Theodoulou, A. Wolff, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Richard L Schilsky, Larry Norton, James N Ingle, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

Donald A. Berry, Eric P. Winer, Larry Norton, 2006 .

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).

E. Winer, E. Perez, C. Hudis, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.

D. Berry, E. Winer, D. Lake, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.

D. Berry, E. Winer, C. Hudis, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.

H. Cohen, E. Winer, J. Foster, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).

H. Cohen, A. Jatoi, J. Ligibel, 2017, Journal of geriatric oncology.

Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541.

D. Berry, M. Roach, D. Hayes, 1997, The cancer journal from Scientific American.

Single brain metastases: surgery plus radiation or radiation alone

H. Thaler, J. Posner, C. Cirrincione, 1986, Neurology.

How much time do nurses spend teaching cancer patients.

C. Cirrincione, M. Bookbinder, P. Agre, 1990, Patient education and counseling.

Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG

D. Berry, E. Winer, E. Perez, 2005 .

Evaluation of malignant lymphomas using three classifications and the working formulation. 482 cases with median follow-up of 11.9 years.

H. Thaler, B. Clarkson, C. Cirrincione, 1986, The American journal of medicine.

Is Body Fat Topography a Risk Factor for Breast Cancer?

C. Cirrincione, J. Petrek, D. Bajorunas, 1993, Annals of Internal Medicine.

Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.

D. Berry, C. Perou, E. Winer, 2013 .

Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al.

Barbara L. Smith, D. Berry, E. Winer, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols.

R. Mertelsmann, C. Cirrincione, D. Straus, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.

D. Berry, L. Norton, D. Hayes, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Reply to V. Amoroso et al.

D. Berry, E. Winer, C. Hudis, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN).

C. Shapiro, C. Fadul, E. Paskett, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis.

L. Recht, H. Thaler, J. Posner, 1988, The American journal of medicine.

Treatment of stages I and II Hodgkin's disease with three different therapeutic modalities.

R. Mertelsmann, B. Clarkson, C. Cirrincione, 1986, The American journal of medicine.

Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia.

R. Mertelsmann, B. Clarkson, C. Cirrincione, 1980, Blood.

The role of HER-2 + Topo IIα amplification in predicting benefit from CAF dose escalation-CALGB 8541.

D. Berry, M. Ellis, D. Cowan, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study.

L. Norton, C. Cirrincione, I. Henderson, 1999, American journal of clinical oncology.

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.

S. Groshen, M. Kris, S. Groshen, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of radiation therapy following resection of single brain metastasis from melanoma

L. Deangelis, H. Thaler, C. Cirrincione, 1990, Neurology.

Analysis of T‐cell subsets in B‐cell chronic lymphocytic leukemia: A correlation with the stage of disease

C. Cirrincione, A. Mittelman, T. Denny, 1984, American journal of hematology.

Immunologic Aspects of Chronic Obstructive Pulmonary Disease

D. Berry, C. Cirrincione, H. Muss, 2009 .

Efficacy and safety of high‐dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma

K. Sullivan, S. Tuchman, B. Peterson, 2017, Hematological oncology.

Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia.

S. Groshen, B. Shank, C. Cirrincione, 1987, The New England journal of medicine.

Abstract PD05-01: CALGB 40302: Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study

E. Winer, D. Lake, W. Barry, 2010 .

CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).

E. Winer, E. Perez, C. Hudis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Cancer and Leukemia Group B Oncology Nursing Committee (1983-2006): A History of Passion, Commitment, Challenge, and Accomplishment

C. Cirrincione, E. Smith, J. Armer, 2006, Clinical Cancer Research.

Multivariate analysis of T‐cell functional defects and circulating serum factors in hodgkin's disease

H. Thaler, N. Day, C. Cirrincione, 1981, Cancer.

Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease.

K. Sullivan, C. Cirrincione, D. Howell, 2018, Archives of pathology & laboratory medicine.

Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.

K. Sullivan, C. Cirrincione, A. Sung, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

Lyndsay Harris, Donald Berry, Larry Norton, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840.

H. Cohen, E. Winer, C. Hudis, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance).

M. Ellis, E. Winer, D. Lake, 2015 .

Current Status of Treatment of Acute Leukemia in Adults: An Overview

R. Dinsmore, M. Andreeff, R. Mertelsmann, 1984 .

A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study.

J. Herndon, S. Luikart, C. Cirrincione, 1996, Lung cancer.

Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.

Barbara L. Smith, D. Berry, E. Winer, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

D. Berry, C. Perou, E. Winer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of T cell subsets in cancer patients treated with interferon.

B. Safai, C. Cirrincione, H. Oettgen, 1983, The American journal of medicine.

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.

D A Berry, D. Berry, L. Norton, 1998, Journal of the National Cancer Institute.

Comparative Analysis ofSurface Membrane Immunoglobulin Determination by Flow Cytometry and Fluorescence

C. Cirrincione, D. Gebhard, Abraham Miitelman, 1986 .

Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.

H. Cohen, D. Berry, E. Winer, 2005, JAMA.

Dihydro‐5‐azacytidine in malignant mesothelioma

M. Citron, J. Herndon, Mark R. Green, 1997, Cancer.

Serum tumor markers in patients with metastatic germ cell tumors of the testis. A 10-year experience.

N. Geller, G. Bosl, W. Whitmore, 1983, The American journal of medicine.

Multivariate analysis of prognostic variables in patients with metastatic testicular cancer.

N. Geller, H. Scher, G. Bosl, 1983, Cancer research.

Interrelationships of histopathology and other clinical variables in patients with germ cell tumors of the testis

N. Geller, G. Bosl, W. Whitmore, 1983, Cancer.

Pulmonary function in preterm infants following treatment with intravenous indomethacin.

H. Thaler, C. Cirrincione, A. Levin, 1989, American journal of diseases of children.

Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease.

C. Cirrincione, D. Armstrong, A. Blevins, 1992, The Journal of infectious diseases.

Morphological Classification, Response to Therapy, and Survival in 263 Adult Patients With Acute Nonlymphoblastic Leukemia

H. Thaler, R. Mertelsmann, B. Clarkson, 1980 .

Malignant melanoma in children

A. Davidoff, H. Seigler, C. Cirrincione, 1994, Annals of Surgical Oncology.

Serum Tumor Markers in Patients With Metastatic Germ Cell Tumors of the Testis

N. Geller, W. Whitmore, C. Cirrincione, 1984 .

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Bingshu E. Chen, D. Berry, P. Fasching, 2019, The Lancet.

Primary CNS lymphoma

G. Krol, L. Deangelis, H. Thaler, 1990, Neurology.

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

D. Berry, C. Perou, E. Winer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

D. Berry, A. Thor, W. Wood, 1994, The New England journal of medicine.

The significance of splenomegaly in 101 adults with acute lymphoblastic leukemia (ALL) at presentation and during remission.

H. Thaler, R. Mertelsmann, B. Clarkson, 1981, Blood.

Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).

D. Berry, E. Winer, C. Hudis, 2017, Journal of the American College of Surgeons.

Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).

D. Berry, E. Winer, C. Hudis, 2015, Annals of surgery.

Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)

D. Berry, C. Perou, E. Winer, 2013 .

Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.

C. Shapiro, C. Fadul, E. Paskett, 2013, JAMA.

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

E. Winer, C. Hudis, W. Barry, 2019, European journal of cancer.

Improved Outcomes From Adding Sequent ia l Pacl i taxe l but Not From Escalat ing Doxorubic in Dose in an Adjuvant Chemotherapy Regimen for Pat ients With Node-Pos i t i ve Pr imary Breast Cancer

D. Berry, R. Schilsky, S. Martino, 2003 .

Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.

D. Berry, E. Winer, R. Schilsky, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.

Larry Norton, Donald A Berry, D. Berry, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.

Barbara L. Smith, D. Berry, E. Winer, 2004, The New England journal of medicine.

Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance).

D. Berry, E. Winer, C. Hudis, 2015 .

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

D. Berry, E. Winer, C. Hudis, 2016, Breast Cancer Research and Treatment.

Standard chemotherapy versus capcitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907.

H. Cohen, D. Berry, E. Winer, 2015 .

Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)

D. Berry, C. Perou, E. Winer, 2016 .

Adjuvant chemotherapy in older women with early-stage breast cancer.

H. Cohen, D. Berry, E. Winer, 2009, The New England journal of medicine.

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

M. Ellis, E. Winer, D. Lake, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401.

H. Cohen, W. Barry, I. Galinsky, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.

D. Berry, M. Ellis, E. Winer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.

D. Berry, C. Cirrincione, D. Rizzieri, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

D. Berry, E. Winer, E. Perez, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907

H. Cohen, E. Winer, C. Hudis, 2008 .

Dose-Response T rial o f M egestrol A cetate i n A dvanced Breast C ancer: C ancer a nd L eukemia G roup B Phase I II S tudy 8 741

D. Berry, L. Norton, J. Abrams, 1999 .

Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741.

D. Berry, L. Norton, J. Abrams, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840.

H. Cohen, E. Winer, C. Hudis, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.

M. Citron, J. Abrams, C. Cirrincione, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous bone marrow transplantation in primary breast cancer : the American experience

J. Fay, L. Akard, C. Cirrincione, 1995 .

Prognostic Value of DNA/RNA Flow Cytometry in Myeloblastic and Lymphoblastic Leukemia in Adults: RNA Content and S‐Phase Predict Remission Duration and Survival in Multi‐Variate Analysis a

M. Andreeff, C. Cirrincione, Gordon Assing, 1986, Annals of the New York Academy of Sciences.

Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced brea

E. Winer, D. Lake, C. Hudis, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective randomized trial of single versus multiple drains in the axilla after lymphadenectomy.

H. Thaler, C. Cirrincione, J. Petrek, 1992, Surgery, gynecology & obstetrics.

Predictors of duloxetine response in patients with oxaliplatin‐induced painful chemotherapy‐induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial – CALGB/alliance 170601

C. Shapiro, C. Loprinzi, C. Fadul, 2017, European journal of cancer care.

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.

H. Cohen, D. Berry, E. Winer, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.

D. Berry, H. Parnes, L. Norton, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)

D. Berry, E. Winer, L. Norton, 2009, Breast Cancer Research and Treatment.

Comparative analysis of surface membrane immunoglobulin determination by flow cytometry and fluorescence microscopy.

H. Thaler, C. Cirrincione, A. Mittelman, 1986, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

The impact of local/regional radiotherapy (RT), and its timing, on survival following lumpectomy/mastectomy and systemic chemotherapy in patients with ≥10 positive axillary nodes: Analysis of CALGB 9082

L. Norton, L. Marks, E. Shpall, 2004 .

Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.

Lawrence B Marks, Jinli Ma, Larry Norton, 2010, International journal of radiation oncology, biology, physics.

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.

G. Rosner, R. Schilsky, L. Norton, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869.

D. Berry, C. Cirrincione, H. Muss, 1995, Cytometry.

Diagnostic and prognostic significance of the CFU-c assay in acute nonlymphoblastic leukemia.

R. Mertelsmann, H. Broxmeyer, B. Clarkson, 1981, Cancer research.

Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance).

D. Berry, E. Mardis, M. Ellis, 2015, Journal of the National Cancer Institute.

Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study.

J. Herndon, C. Cirrincione, M. Green, 1995, Lung cancer.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

413 Relationship Between Body Mass Index (BMI) and Outcomes in Node-positive Breast Cancer Patients Receiving Chemotherapy–Results From CALGB/Intergroup 9741

D. Berry, E. Winer, C. Hudis, 2012 .

Paradigm Shift in Adjuvant Treatment of Receptor Positive Premenopausal Breast Cancer Patients ? Not Yet !

Barbara L. Smith, D. Berry, E. Winer, 2003 .

Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance).

D. Berry, E. Winer, C. Hudis, 2013 .

Methodological considerations in the design and implementation of clinical trials.

H. Pang, C. Cirrincione, Ellen M. Lavoie Smith, 2014, Seminars in oncology nursing.

Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy.

G. Krol, L. Deangelis, H. Thaler, 1990 .

Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.

C. Shapiro, C. Fadul, E. Paskett, 2013, JAMA.

Statistical approach to measuring analgesic response

H. Thaler, C. Cirrincione, R. Portenoy, 1990, Pain.

E. Winer, E. Perez, C. Hudis, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.